Etrein是Etretinate(依曲替酯)的代谢水解物,在体内的半衰期仅2～4天。本文作者报告了用Etretin治疗严重全身性银屑病的双盲研究和开放试验结果。方法:21例皮损面积达21%～95%银屑病患者,随机分成不同治疗组,分别用Etretin每日0.15、50或75 mg,即相当于每天每公斤体重0、0.14、0.66或0.85 mg的平均剂量。共治疗8周(双盲研究)。随后,患者继续用Etretin治疗,根据临床反应决定 Etrein is a metabolite hydrolyzate of Etretinate with a half-life in vivo of only 2 to 4 days. The authors report the results of double-blind studies and open-label trials of Etretin in the treatment of severe systemic psoriasis. METHODS: Twenty-one patients with lesions of 21% to 95% psoriasis were randomly assigned to treatment groups treated with Etretin 0.15, 50 or 75 mg daily, equivalent to 0, 0.14, 0.66, or 0.85 kg body weight per day The average dose of mg. A total of 8 weeks of treatment (double-blind study). Subsequently, the patient continues to be treated with Etretin, based on the clinical response